AN2 Therapeutics ANTX Institutional Ownership

Updated Oct 10, 2026

AN2 Therapeutics, Inc. (NASDAQ:ANTX) appeared in the 13F filings of 66 institutional investors for the quarter ended June 30, 2026.

• Together they owned 54.92% of the outstanding stock in Q2 2026, down from 59.41% a quarter earlier.
• Total holdings of AN2 Therapeutics shares rose 14.99% from Q1 2026, and the number of holders rose 88.57% from Q2 2025.
• Of these 66 holders, 44 added to their positions, 13 reduced their stakes and 9 left their positions unchanged.
• The aggregate institutional position in AN2 Therapeutics was 24.58Mn shares at the end of Q2 2026, up 3.21Mn from the prior quarter and up 16.49Mn from a year earlier.
• Vivo Capital, LLC held the largest position in ANTX at 3.15Mn shares as of June 30, 2026, or 7.05% of shares outstanding.
• The biggest increases in ANTX positions during Q2 2026 came from BlackRock, Inc. (+1.35Mn shares), Citadel Advisors LLC (+796.76K shares), Commodore Capital LP (+599.97K shares), Geode Capital Management, LLC (+411.26K shares) and Vanguard Capital Management LLC (+227.63K shares).
• The largest position reductions in ANTX for Q2 2026 were by Woodline Partners LP (-533.87K shares), Bank of America Corp (-247.9K shares), Morgan Stanley (-184.81K shares), Stonepine Capital Management, LLC (-162.15K shares) and Ameriprise Financial Inc (-159.12K shares).
• AN2 Therapeutics' 10 largest institutional shareholders as of Q2 2026 were Vivo Capital, LLC (3.15Mn shares), Commodore Capital LP (2.93Mn shares), Millennium Management LLC (2.32Mn shares), BlackRock, Inc. (1.67Mn shares), Spruce Street Capital LP (1.66Mn shares), Almitas Capital LLC (1.47Mn shares), Vanguard Capital Management LLC (1.24Mn shares), Adage Capital Partners GP, L.L.C. (1Mn shares), Citadel Advisors LLC (952K shares) and Boxer Capital Management, LLC (749.03K shares), per Business Quant data.